Genexine: Major Management Disclosure: GXI7 Milestone Payment Claim
AI reading
★★★★ Bullish · Material event
Receipt of Milestone Payment Following Completion of GX-I7 Phase 2 Clinical Trial
Key figures: Amount Received: USD 3,000,000 (approx. ₩4.2bn)
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
For information only. Not investment advice.